ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Covance sees Asia as key market for CRO business

Covance CEO Deborah Keller

NEW YORK -- CROs, or Contract Research Organizations, are expanding as rising demand for new medicines spurs pharmaceutical companies to seek more cost-effective research and development. The organizations provide support to the pharmaceutical, biotechnology, and medical device industries in the form of research services outsourced on a contract basis. The Nikkei recently spoke with Deborah Keller, CEO of Covance, a leading U.S. CRO, about the industry's growing role and the importance of the Asian market.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more